经皮冠脉介入法围术期替格瑞洛联合替罗非班抗血小板出血风险临床观察

目的:观察经皮冠脉介入法(percutaneous coronary intervention,PCI)围术期替格瑞洛联合替罗非班抗血小板出血风险。方法:回顾性分析我院急性冠脉综合征并成功完成PCI手术的患者328例,其中替格瑞洛组172例,氢氯吡格雷组156例,所有患者均在术后给予替罗非班11.5 h,并长期口服阿司匹林100 mg,1次/d。分析患者临床资料观察PCI术后30 d内出血情况。结果:两组患者间一般情况、危险因素、临床资料、临床用药及PCI数据等均无统计学意义。替格瑞洛联合替罗非班组和氢氯吡格雷联合替罗非班组,两组均未见致命性出血患者。替格瑞洛组发生非致命性出血发生率为9.30%;氯吡格雷组为7.05%,两组比较差异无统计学意义(χ2=0.157,P>0.05)。结论:与氢氯吡格雷相比,PCI术后替格瑞洛联合替罗非班不会增加患者的出血风险。

Clinical observation of bleeding risk on patients treated with ticagrelor and tirofiban during perioperative period of percutaneous coronary intervention

Objective:To observe the bleeding risk in patients treated with ticagrelor and tirofiban during perioperative period of percutaneous coronary intervention. Methods:A retrospective analysis of 328 patients with ACS who accepted PCI therapy in our hos-pital was performed. 172 cases were administrated ticagrelor and 156 cases were given clopidogrel. All patients were administrated tirofi-ban by intravenous transfusion for 11 hours and 30 minutes and aspirin 100 mg per day after PCI. The clinical bleeding data of the pa-tients within 30 days were analyzed. Results:There was no significant difference between two groups in general,risk factors,clinical da-ta,clinical medication and PCI data. No fatal hemorrhage was found in both groups. Non-fatal bleeding in ticagrelor group occurred in 9. 30%,in clopidogrel group 7. 05%,and the difference between the two groups had no statistical significance (P>0. 05). Conclusion:Compared with clopidogrel,ticagrelor combined with tirofiban did not increase the risk of hemorrhage patients after PCI.